Objective: Detrusor hyperactivity with impaired contractility (DHIC) is not an uncommon bladder disorder, and is often difficult to treat. Therefore, using a rat model featuring both urinary frequency and residual urine, we investigated whether an anticholinergic agent (solifenacin) or a β3-agonist (mirabegron) is more suitable to combine with distigmine to treat DHIC. Methods: The partial bladder outlet obstruction (BOO) rat model was used. Rats were treated for 2 weeks: BOO/Solifenacin group was treated with 0.1 mg/kg solifenacin (n = 8), BOO/Mirabegron group was treated with 1 mg/kg mirabegron (n = 8), BOO/- group was not drug-treated but was given distilled water (n = 8), and the control group was also given distilled water (n = 8). Then the urethral ligature was removed under urethane anesthesia, and continuous cystometry was performed to evaluate bladder function. Baseline measurements were taken, then distigmine was administered to all groups, and cystometry was performed again to measure changes in bladder function. Results: Residual volumes increased in the BOO/- group, and the detrusor contractions were more frequent than that of the control group. Solifenacin treatment did not influence changes, except for threshold pressure, to any cystometric measurements. However, mirabegron treatment decreased the residual volume and residual volume rate; it also decreased detrusor contraction frequency similar to measurements obtained from the control group. Distigmine treatment enhanced detrusor contractions, which resulted in less residual volume, and decreased detrusor contraction frequency in the BOO model. Conclusions: The combination of distigmine and mirabegron was determined to be a better treatment than the combination of distigmine and solifenacin for DHIC.
References
[1]
Haferkamp, A., Dörsam, J., Resnick, N.M., Yalla, S.V. and Elbadawi, A. (2003) Structural Basis of Neurogenic Bladder Dysfunction. II. Myogenic Basis of Detrusor Hyperreflexia. The Journal of Urology, 169, 547-554. https://doi.org/10.1016/S0022-5347(05)63951-1
[2]
Lee, W.C., Wu, H.P., Tai, T.Y., Yu, H.J. and Chiang, P.H. (2009) Investigation of Urodynamic Characteristics and Bladder Sensory Function in the Early Stages of Diabetic Bladder Dysfunction in Women with Type 2 Diabetes. The Journal of Urology, 181, 198-203. https://doi.org/10.1016/j.juro.2008.09.021
[3]
Liao, C.H., Chung, S.D. and Kuo, H.C. (2011) Diagnostic Value of International Prostate Symptom Score Voiding-to-Storage Subscore Ratio in Male Lower Urinary Tract Symptoms. International Journal of Clinical Practice, 65, 552-558. https://doi.org/10.1111/j.1742-1241.2011.02638.x
[4]
Yamaguchi, O., Marui, E., Kakizaki, H., Itoh, N., Yokota, T., Okada, H., Ishizuka, O., Ozono, S., Gotoh, M., Sugiyama, T., Seki, N., Yoshida, M. and Japanese Solifenacin Study Group (2007) Randomized, Double-Blind, Placebo- and Propiverine-Controlled Trial of the Once-Daily Antimuscarinic Agent Solifenacin in Japanese Patients with Overactive Bladder. BJU International, 100, 579-587. https://doi.org/10.1111/j.1464-410X.2007.07031.x
[5]
Cardozo, L., Hessdörfer, E., Milani, R., Arañó, P., Dewilde, L., Slack, M., Drogendijk, T., Wright, M., Bolodeoku, J. and SUNRISE Study Group (2008) Solifenacin in the Treatment of Urgency and Other Symptoms of Overactive Bladder: Results from a Randomized, Double Blind, Placebo-Controlled, Rising-Dose Trial. BJU International, 102, 1120-1127. https://doi.org/10.1111/j.1464-410X.2008.07939.x
[6]
Bougas, D.A., Mitsogiannis, I.C., Mitropoulos, D.N., Kollaitis, G.C., Serafetinides, E.N. and Giannopoulos, A.M. (2004) Clinical Efficacy of Distigmine Bromide in the Treatment of Patients with Underactive Detrusor. International Urology and Nephrology, 36, 507-512. https://doi.org/10.1007/s11255-004-0847-8
[7]
Yamanishi, T., Yasuda, K., Kamai, T., Tsujii, T., Sakakibara, R., Uchiyama, T. and Yoshida, K. (2004) Combination of a Cholinergic Drug and an Alpha-Blocker Is More Effective than Monotherapy for the Treatment of Voiding Difficulty in Patients with Underactive Detrusor. International Journal of Urology, 11, 88-96. https://doi.org/10.1111/j.1442-2042.2004.00753.x
[8]
Chapple, C.R., Herschorn, S., Abrams, P., Wang, J.T., Brodsky, M. and Guan, Z. (2010) Efficacy and Safety of Tolterodine Extended-Release in Men with Overactive Bladder Symptoms Treated with an α-Blocker: Effect of Baseline Prostate-Specific Antigen Concentration. BJU International, 106, 1332-1338. https://doi.org/10.1111/j.1464-410X.2010.09359.x
[9]
Sugaya, K., Nishijima, S., Kadekawa, K., Ashitomi, K. and Yamamoto, H. (2012) Effect of Distigmine Combined with Propiverine on Bladder Activity in Rats with Spinal Cord Injury. International Journal of Urology, 19, 480-483. https://doi.org/10.1111/j.1442-2042.2011.02953.x
[10]
Chapple, C.R., Cardozo, L., Nitti, V.W., Siddiqui, E. and Michel, M.C. (2014) Mirabegron in Overactive Bladder: A Review of Efficacy, Safety, and Tolerability. Neurourology and Urodynamics, 33, 17-30. https://doi.org/10.1002/nau.22505
[11]
Yamaguchi, O., Marui, E., Igawa, Y., Takeda, M., Nishizawa, O., Ikeda, Y. and Ohkawa, S. (2015) Efficacy and Safety of the Selective β3-Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study. Lower Urinary Tract Symptoms, 7, 84-92. https://doi.org/10.1111/luts.12053
[12]
Michel, M.C. (2011) β-Adrenergic Receptor Subtypes in the Urinary Tract. Handbook of Experimental Pharmacology, 202, 307-318. https://doi.org/10.1007/978-3-642-16499-6_15
[13]
Alexandre, E.C., Kiguti, L.R., Calmasini, F.B., Silva, F.H., da Silva, K.P., Ferreira, R., Ribeiro, C.A., Mónica, F.Z., Pupo, A.S. and Antunes, E. (2016) Mirabegron Relaxes Urethral Smooth Muscle by a Dual Mechanism Involving β3-Adrenoceptor Activation and α1-Adrenoceptor Blockade. British Journal of Pharmacology, 173, 415-428. https://doi.org/10.1111/bph.13367
[14]
Miyazaki, N., Yamaguchi, O., Nomiya, M., Aikawa, K. and Kimura, J. (2016) Preventive Effect of Hydrogen Water on the Development of Detrusor Overactivity in a Rat Model of Bladder Outlet Obstruction. The Journal of Urology, 195, 780-787. https://doi.org/10.1016/j.juro.2015.10.117
[15]
Ohtake, A., Saitoh, C., Yuyama, H., Ukai, M., Okutsu, H., Noguchi, Y., Hatanaka, T., Suzuki, M., Sato, S., Sasamata, M. and Miyata, K. (2007) Pharmacological Characterization of a New Antimuscarinic Agent, Solifenacin Succinate, in Comparison with Other Antimuscarinic Agents. Biological and Pharmaceutical Bulletin, 30, 54-58. https://doi.org/10.1248/bpb.30.54
[16]
Suzuki, M., Ohtake, A., Yoshino, T., Yuyama, H., Hayashi, A., Ukai, M., Okutsu, H., Noguchi, Y., Sato, S. and Sasamata, M. (2005) Effects of Solifenacin Succinate (YM905) on Detrusor Overactivity in Conscious Cerebral Infarcted Rats. European Journal of Pharmacology, 512, 61-66. https://doi.org/10.1016/j.ejphar.2005.02.023
[17]
Yoshida, M., Masunaga, K., Nagata, T., Maeda, Y., Miyamoto, Y., Kudoh, J. and Homma, Y. (2009) Attenuation of Non-Neuronal Adenosine Triphosphate Release from Human Bladder Mucosa by Antimuscarinic Agents. Lower Urinary Tract Symptoms, 1, 88-92. https://doi.org/10.1111/j.1757-5672.2009.00049.x
[18]
Ohtake, A., Sato, S., Sasamata, M. and Miyata, K. (2010) The Forefront for Novel Therapeutic Agents Based on the Pathophysiology of Lower Urinary Tract Dysfunction: Ameliorative Effect of Solifenacin Succinate (Vesicare), a Bladder-Selective Antimuscarinic Agent, on Overactive Bladder Symptoms, Especially Urgency Episodes. Journal of Pharmacological Sciences, 112, 135-141. https://doi.org/10.1254/jphs.09R13FM
[19]
Takasu, T., Ukai, M., Sato, S., Matsui, T., Nagase, I., Maruyama, T., Sasamata, M., Miyata, K., Uchida, H. and Yamaguchi, O. (2007) Effect of (R)-2-(2-aminothiazol-4-yl)-4-(2-(2-hydroxy-2-phenyltheyl)amino)ethyl)acetanilide (YM178), a Novel Selective Beta 3-Adrenoceptor Agonist on Bladder Function. Journal of Pharmacology and Experimental Therapeutics, 321, 642-647. https://doi.org/10.1124/jpet.106.115840
[20]
Aizawa, N., Homma, Y. and Igawa, Y. (2012) Effects of Mirabegron, a Novel β3-Adrenoceptor Agonist, on Primary Bladder Afferent Activity and Bladder Microcontractions in Rats Compared with the Effects of Oxybutynin. European Urology, 62, 1165-1173. https://doi.org/10.1016/j.eururo.2012.08.056
[21]
Sacco, E. and Bientinesi, R. (2012) Mirabegron: A Review of Recent Data and Its Prospects in the Management of Overactive Bladder. Therapeutic Advances in Urology, 4, 315-324. https://doi.org/10.1177/1756287212457114
[22]
Takeda, M., Obara, K., Mizusawa, T., Tomita, Y., Arai, K., Tsutsui, T., Hatano, A., Takahashi, K. and Nomura, S. (1999) Evidence for beta-3-AR Subtypes in Relaxation of the Human Urinary Bladder Detrusor: Analysis by Molecular Biological and Pharmacological Methods. Journal of Pharmacology and Experimental Therapeutics, 288, 1367-1373.
[23]
Hatanaka, T., Ukai, M., Watanabe, M., Someya, A., Ohtake, A., Suzuki, M., Ueshima, K., Sato, S. and Kaku, S. (2013) Effect of Mirabegron, a Novel β3-Adrenoceptor Agonist, on Bladder Function during Storage Phase in Rats. Naunyn-Schmiedeberg’s Archives of Pharmacology, 386, 71-78. https://doi.org/10.1007/s00210-012-0814-3
[24]
Woods, M., Carson, N., Norton, N., Sheldon, J. and Argentieri, T. (2001) Efficacy of the Beta-3-adrenergic Receptor Agonist CL-316243 on Experimental Bladder Hyperreflexia and Detrusor Instability in the Rat. The Journal of Urology, 166, 1142-1147. https://doi.org/10.1016/S0022-5347(05)65936-8
[25]
Sekiya, S., Michikawa, H., Tanaka, Y. and Koike, K. (2006) Effects of Distigmine on the Intraurethral Pressure of Anesthetized Guinea-Pigs. Pharmacometrics, 71, 19-27.
[26]
Sekiya, S., Ookawa, N., Horinouchi, T., Tanaka, Y. and Koike, K. (2006) Effects of Distigmine, a Long-Acting Cholinesterase Inhibitor, on Urinary Bladder Contractile. Functions Assessed by Using Cystometry Method in Anesthetized Guinea-Pigs. Pharmacometrics, 70, 29-34.
[27]
Wöllner, J. and Pannek, J. (2016) Initial Experience with the Treatment of Neurogenic Detrusor Overactivity with a New β-3 Agonist (Mirabegron) in Patients with Spinal Cord Injury. Spinal Cord, 54, 78-82. https://doi.org/10.1038/sc.2015.195
[28]
Lee, C.L. and Kuo, H.C. (2019) Efficacy and Safety of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Detrusor Hyperactivity and Impaired Contractility. Lower Urinary Tract Symptoms, 11, O93-O97. https://doi.org/10.1111/luts.12224
